Cheng-Ming Chiang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Cheng-Ming Chiang has a total of 295 co-authors. Here are the top co-authors by number of shared publications:
Shwu-Yuan Wu
12 shared publicationsHsien-Tsung Lai
Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas 75390, United States
6 shared publicationsA-Young Lee
Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA; Department of Pharmacology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
5 shared publications- Liang Ouyang
Sichuan University
3 shared publications - Amos Hong Pheng Loh
Department of Paediatric Surgery, KK Women's and Children's Hospital, Singapore
2 shared publications - Andrey Ignatov
ETH Zurich
2 shared publications
Latest Publications
- Open Access
Deciphering the Network Architecture of APOBEC3-Driven Mutagenesis in HPV-Positive Head and Neck Cancers
2 APOBEC3A (A3A) and APOBEC3B (A3B) are cytosine deaminases that restrict viral infection and can also mutate the host genome. In human papillomavirus (HPV)-positive head and neck squamous cell carcinoma (HNSCC), expression of both enzymes is elevated, but bulk sequencing averages their effects across mixed cell populations. Here we profile single cells from HPV16-positive HNSCC tumors and matched normal tissue. We find that the APOBEC3 (A3) single base substitution mutational signature, SBS2, is enriched in cells expressing more A3A than A3B , whereas copy number alteration (CNA) burden is enriched in cells expressing more A3B than A3A . Tumor versus normal co-expression networks identify the A3 interactors RALY and HNRNPA2B1 as candidate A3 activators. We find that SBS2 and CNA mark the maintenance and virus assembly stages of the HPV16 life cycle, and their ratio may offer a molecular estimate of tumor age. The neoantigens from immune-visible SBS2-HIGH and immune-evasive CNA-HIGH cells identify candidates for mRNA vaccines matched to a tumor’s viral state. 3 Significance: Single-cell analysis of HPV-positive HNSCC reveals that DNA editing enzymes A3A and A3B associate with distinct HPV16 life cycle stages and immunological tumor states, enabling stage-matched neoantigen vaccine candidate identification for personalized immunotherapy.
Open AccessDeciphering the Network Architecture of APOBEC3-Driven Mutagenesis in HPV-Positive Head and Neck Cancers
2 APOBEC3A (A3A) and APOBEC3B (A3B) are cytosine deaminases that restrict viral infection and can also mutate the host genome. In human papillomavirus (HPV)-positive head and neck squamous cell carcinoma (HNSCC), expression of both enzymes is elevated, but bulk sequencing averages their effects across mixed cell populations. Here we profile single cells from HPV16-positive HNSCC tumors and matched normal tissue. We find that the APOBEC3 (A3) single base substitution mutational signature, SBS2, is enriched in cells expressing more A3A than A3B , whereas copy number alteration (CNA) burden is enriched in cells expressing more A3B than A3A . Tumor versus normal co-expression networks identify the A3 interactors RALY and HNRNPA2B1 as candidate A3 activators. We find that SBS2 and CNA mark the maintenance and virus assembly stages of the HPV16 life cycle, and their ratio may offer a molecular estimate of tumor age. The neoantigens from immune-visible SBS2-HIGH and immune-evasive CNA-HIGH cells identify candidates for mRNA vaccines matched to a tumor’s viral state. 3 Significance: Single-cell analysis of HPV-positive HNSCC reveals that DNA editing enzymes A3A and A3B associate with distinct HPV16 life cycle stages and immunological tumor states, enabling stage-matched neoantigen vaccine candidate identification for personalized immunotherapy.
- 23 July 2026
- Published by Elsevier in Molecular Cell
- Vol. 86 (17) , 3367-3393
BRD4: From molecular understanding to therapeutics development
- 23 July 2026
- Published by Elsevier in Molecular Cell
- Vol. 86 (17) , 3367-3393
BRD4: From molecular understanding to therapeutics development
- 12 March 2024
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 7 (4) , 1178-1190
Novel BRD4-p53 Inhibitor SDU-071 Suppresses Proliferation and Migration of MDA-MB-231 Triple-Negative Breast Cancer Cells
A promising alternative for cancer treatment involves targeted inhibition of the epigenetic regulator bromodomain-containing protein 4 (BRD4); however, available BRD4 inhibitors are constrained by their potency, oral bioavailability, and cytotoxicity. Herein, to overcome the drawback of the translational BRD4 inhibitors, we describe a novel BRD4-p53 inhibitor, SDU-071, which suppresses BRD4 interaction with the p53 tumor suppressor and its biological activity in MDA-MB-231 triple-negative breast cancer (TNBC) cells in vitro and in vivo. This novel small-molecule BRD4-p53 inhibitor suppresses cell proliferation, migration, and invasion by downregulating the expression of BRD4-targeted genes, such as c-Myc and Mucin 5AC, and inducing cell cycle arrest and apoptosis, as demonstrated in cultured MDA-MB-231 TNBC cells. Its antitumor activity is illustrated in an orthotopic mouse xenograft mammary tumor model. Overall, our results show that SDU-071 is a viable option for potentially treating TNBC as a new BRD4-p53 inhibitor.
- 12 March 2024
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 7 (4) , 1178-1190
Novel BRD4-p53 Inhibitor SDU-071 Suppresses Proliferation and Migration of MDA-MB-231 Triple-Negative Breast Cancer Cells
A promising alternative for cancer treatment involves targeted inhibition of the epigenetic regulator bromodomain-containing protein 4 (BRD4); however, available BRD4 inhibitors are constrained by their potency, oral bioavailability, and cytotoxicity. Herein, to overcome the drawback of the translational BRD4 inhibitors, we describe a novel BRD4-p53 inhibitor, SDU-071, which suppresses BRD4 interaction with the p53 tumor suppressor and its biological activity in MDA-MB-231 triple-negative breast cancer (TNBC) cells in vitro and in vivo. This novel small-molecule BRD4-p53 inhibitor suppresses cell proliferation, migration, and invasion by downregulating the expression of BRD4-targeted genes, such as c-Myc and Mucin 5AC, and inducing cell cycle arrest and apoptosis, as demonstrated in cultured MDA-MB-231 TNBC cells. Its antitumor activity is illustrated in an orthotopic mouse xenograft mammary tumor model. Overall, our results show that SDU-071 is a viable option for potentially treating TNBC as a new BRD4-p53 inhibitor.
- 15 January 2024
- Published by H1 Connect
Faculty Opinions recommendation of Overcoming therapeutic resistance in oncolytic herpes virotherapy by targeting IGF2BP3-induced NETosis in malignant glioma.
This paper identifies insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) as a key reader protein for N6-methyladenosine (m6A)-modified colony-stimulating factor 3 (CSF3) and mindbomb 1 (MIB1, an E3 ubiquitin ligase) mRNAs, leading to enhanced CSF3 and MIB1 mRNA and protein levels that increase respectively neutrophil extracellular trap (NET) formation and degradation of FTO m6A-demethylase thus promoting glioma tumor progression through the IGF2BP3/MIB3/FTO-regulated m6A CSF3 pathway. Importantly, while oncolytic herpes simplex virus (oHSV) unexpectedly stimulates NET formation and m6A levels and counterintuitively contributes to glioma development, its antitumor activity is fully unleashed by cotreatment of intratumor oHSV infection with bromodomain-containing protein 4 (BRD4) inhibitor JQ1 or I-BET151 that inhibits IGF3BP3 and overall m6A levels but enhances oHSV replication, resulting in significantly reduced glioma tumor weight/volume and effective oncolytic virotherapy.
- 15 January 2024
- Published by H1 Connect
Faculty Opinions recommendation of Overcoming therapeutic resistance in oncolytic herpes virotherapy by targeting IGF2BP3-induced NETosis in malignant glioma.
This paper identifies insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) as a key reader protein for N6-methyladenosine (m6A)-modified colony-stimulating factor 3 (CSF3) and mindbomb 1 (MIB1, an E3 ubiquitin ligase) mRNAs, leading to enhanced CSF3 and MIB1 mRNA and protein levels that increase respectively neutrophil extracellular trap (NET) formation and degradation of FTO m6A-demethylase thus promoting glioma tumor progression through the IGF2BP3/MIB3/FTO-regulated m6A CSF3 pathway. Importantly, while oncolytic herpes simplex virus (oHSV) unexpectedly stimulates NET formation and m6A levels and counterintuitively contributes to glioma development, its antitumor activity is fully unleashed by cotreatment of intratumor oHSV infection with bromodomain-containing protein 4 (BRD4) inhibitor JQ1 or I-BET151 that inhibits IGF3BP3 and overall m6A levels but enhances oHSV replication, resulting in significantly reduced glioma tumor weight/volume and effective oncolytic virotherapy.
- 10 January 2024
- Published by H1 Connect
Faculty Opinions recommendation of Targeted Protein Degradation through Recruitment of the CUL4 Complex Adaptor Protein DDB1.
This paper reports the identification by activity-based protein profiling and cysteine (C) chemoproteomic screening of covalent ligands (e.g., MM-02-57) binding to C173 of DNA damage-binding protein 1 (DDB1), which is a substrate-binding adaptor of the Cullin-4A and Cullin-4B E3 ubiquitin ligases, that when conjugated with different lengths of alkyl linkers to JQ1 that binds to bromodomain-binding protein 4 (BRD4), thus creating MM-02-08 containing a C5 alkyl linker, could selectively induce degradation of BRD4 short isoform (BRD4-S) protein but not BRD4 long isoform (BRD4-L) in a proteosome/NEDDylation/DDB1-dependent manner. However, selective degradation of BRD4-S seen in human embryonic kidney HEK293T cells were not seen in MDA-MB-231 breast cancer cells where MM-02-08 triggers degradation of both BRD4-S and BRD4-L, indicating a cell-specific effect of this newly identified BRD4 PROTAC (proteolysis targeting chimera) heterobifunctional recruiter whose action could be potentially influenced by the cellular proteome and BRD4 isoform-interacting networks at the time of compound action.
- 10 January 2024
- Published by H1 Connect
Faculty Opinions recommendation of Targeted Protein Degradation through Recruitment of the CUL4 Complex Adaptor Protein DDB1.
This paper reports the identification by activity-based protein profiling and cysteine (C) chemoproteomic screening of covalent ligands (e.g., MM-02-57) binding to C173 of DNA damage-binding protein 1 (DDB1), which is a substrate-binding adaptor of the Cullin-4A and Cullin-4B E3 ubiquitin ligases, that when conjugated with different lengths of alkyl linkers to JQ1 that binds to bromodomain-binding protein 4 (BRD4), thus creating MM-02-08 containing a C5 alkyl linker, could selectively induce degradation of BRD4 short isoform (BRD4-S) protein but not BRD4 long isoform (BRD4-L) in a proteosome/NEDDylation/DDB1-dependent manner. However, selective degradation of BRD4-S seen in human embryonic kidney HEK293T cells were not seen in MDA-MB-231 breast cancer cells where MM-02-08 triggers degradation of both BRD4-S and BRD4-L, indicating a cell-specific effect of this newly identified BRD4 PROTAC (proteolysis targeting chimera) heterobifunctional recruiter whose action could be potentially influenced by the cellular proteome and BRD4 isoform-interacting networks at the time of compound action.
- 8 January 2024
- Published by H1 Connect
Faculty Opinions recommendation of Phosphorylation regulates viral biomolecular condensates to promote infectious progeny production.
This paper reports that phosphorylation of an intrinsically disordered region (IDR) of adenovirus (AdV) L1-52/55 kDa protein (52K) promotes viral genome packaging and capsid assembly by transitioning 52K-mediated biomolecular condensates (BMCs) into more liquid-like entities needed for progeny particle production without altering 52K interaction with the viral genome and its partner proteins. Via modulating distinct forms of viral BMCs in sub-cellular compartments, specific IDR-targeting compounds can be developed as antiviral agents to disrupt or enhance specific types of viral BMCs, thereby controlling the infection and viral life cycle.
- 8 January 2024
- Published by H1 Connect
Faculty Opinions recommendation of Phosphorylation regulates viral biomolecular condensates to promote infectious progeny production.
This paper reports that phosphorylation of an intrinsically disordered region (IDR) of adenovirus (AdV) L1-52/55 kDa protein (52K) promotes viral genome packaging and capsid assembly by transitioning 52K-mediated biomolecular condensates (BMCs) into more liquid-like entities needed for progeny particle production without altering 52K interaction with the viral genome and its partner proteins. Via modulating distinct forms of viral BMCs in sub-cellular compartments, specific IDR-targeting compounds can be developed as antiviral agents to disrupt or enhance specific types of viral BMCs, thereby controlling the infection and viral life cycle.
- Open Access
- 8 January 2024
- Published by Springer Nature in EMBO Reports
- Vol. 25 (2) , 832-852
BRD4 isoforms have distinct roles in tumour progression and metastasis in rhabdomyosarcoma
BRD4, a bromodomain and extraterminal (BET) protein, is deregulated in multiple cancers and has emerged as a promising drug target. However, the function of the two main BRD4 isoforms (BRD4-L and BRD4-S) has not been analysed in parallel in most cancers. This complicates determining therapeutic efficacy of pan-BET inhibitors. In this study, using functional and transcriptomic analysis, we show that BRD-L and BRD4-S isoforms play distinct roles in fusion negative embryonal rhabdomyosarcoma. BRD4-L has an oncogenic role and inhibits myogenic differentiation, at least in part, by activating myostatin expression. Depletion of BRD4-L in vivo impairs tumour progression but does not impact metastasis. On the other hand, depletion of BRD4-S has no significant impact on tumour growth, but strikingly promotes metastasis in vivo. Interestingly, BRD4-S loss results in the enrichment of BRD4-L and RNA Polymerase II at integrin gene promoters resulting in their activation. In fusion positive alveolar rhabdomyosarcoma, BRD4-L is unrestricted in its oncogenic role, with no evident involvement of BRD4-S. Our work unveils isoform-specific functions of BRD4 in rhabdomyosarcoma.
- 8 January 2024
- Published by Springer Nature in EMBO Reports
- Vol. 25 (2) , 832-852
Open AccessBRD4 isoforms have distinct roles in tumour progression and metastasis in rhabdomyosarcoma
BRD4, a bromodomain and extraterminal (BET) protein, is deregulated in multiple cancers and has emerged as a promising drug target. However, the function of the two main BRD4 isoforms (BRD4-L and BRD4-S) has not been analysed in parallel in most cancers. This complicates determining therapeutic efficacy of pan-BET inhibitors. In this study, using functional and transcriptomic analysis, we show that BRD-L and BRD4-S isoforms play distinct roles in fusion negative embryonal rhabdomyosarcoma. BRD4-L has an oncogenic role and inhibits myogenic differentiation, at least in part, by activating myostatin expression. Depletion of BRD4-L in vivo impairs tumour progression but does not impact metastasis. On the other hand, depletion of BRD4-S has no significant impact on tumour growth, but strikingly promotes metastasis in vivo. Interestingly, BRD4-S loss results in the enrichment of BRD4-L and RNA Polymerase II at integrin gene promoters resulting in their activation. In fusion positive alveolar rhabdomyosarcoma, BRD4-L is unrestricted in its oncogenic role, with no evident involvement of BRD4-S. Our work unveils isoform-specific functions of BRD4 in rhabdomyosarcoma.
- 15 December 2023
- Published by Elsevier in Molecular Cell
- Vol. 84 (2) , 202-220.e15
IDR-targeting compounds suppress HPV genome replication via disruption of phospho-BRD4 association with DNA damage response factors
- 15 December 2023
- Published by Elsevier in Molecular Cell
- Vol. 84 (2) , 202-220.e15
IDR-targeting compounds suppress HPV genome replication via disruption of phospho-BRD4 association with DNA damage response factors
- 24 November 2023
- Published by H1 Connect
Faculty Opinions recommendation of Epigenetic regulation of asymmetric cell division by the LIBR-BRD4 axis.
This paper identifies long noncoding RNA (lncRNA) CTD-2036P10.5 (nucleotides 241-440) binding to the 5’ untranslated region (5’UTR, nucleotides 150-186) of bromodomain-containing protein 4 (BRD4) mRNA, thus named LIBR (lncRNA inhibiting BRD4), leading to inhibition of BRD4 mRNA translation implicated in asymmetric cell division (ACD) via LIBR-mediated recruitment of a translation repressor RCK and preventing BRD4 mRNA association with polysomes. LIBR-reduced BRD4 protein levels result in diminished transcription of the BRD4-regulated integrin subunit beta 1 (ITGB1) gene locus enriched in nascent BRD4-associated H3K56Ac promoter histone marks typically found in the ACD daughter cells, implying that pharmaceutical inhibition of BRD4 through the use of broad BRD4 chromatin-binding inhibitors such as JQ1 and I-BET may lead to suppression of ACD and thus increase symmetric cell division associated with cancer stem cells that further promote cancer progression and therapy resistance.
- 24 November 2023
- Published by H1 Connect
Faculty Opinions recommendation of Epigenetic regulation of asymmetric cell division by the LIBR-BRD4 axis.
This paper identifies long noncoding RNA (lncRNA) CTD-2036P10.5 (nucleotides 241-440) binding to the 5’ untranslated region (5’UTR, nucleotides 150-186) of bromodomain-containing protein 4 (BRD4) mRNA, thus named LIBR (lncRNA inhibiting BRD4), leading to inhibition of BRD4 mRNA translation implicated in asymmetric cell division (ACD) via LIBR-mediated recruitment of a translation repressor RCK and preventing BRD4 mRNA association with polysomes. LIBR-reduced BRD4 protein levels result in diminished transcription of the BRD4-regulated integrin subunit beta 1 (ITGB1) gene locus enriched in nascent BRD4-associated H3K56Ac promoter histone marks typically found in the ACD daughter cells, implying that pharmaceutical inhibition of BRD4 through the use of broad BRD4 chromatin-binding inhibitors such as JQ1 and I-BET may lead to suppression of ACD and thus increase symmetric cell division associated with cancer stem cells that further promote cancer progression and therapy resistance.
- 5 November 2023
- Published by H1 Connect
Faculty Opinions recommendation of DAXX drives de novo lipogenesis and contributes to tumorigenesis.
This paper characterizes the oncogenic effects of death domain-associated protein 6 (DAXX) on intracellular lipogenesis primarily in MDA-MB-231 triple-negative breast cancer (TNBC) cells and identified that both N- and C-terminal SUMO-interacting motifs (SIMs) of DAXX are crucial for DAXX interaction with sterol regulatory element-binding protein 1 and 2 (SREBP1/2) precursors as well as cleaved SREBP1a, SREBP1c, and SREBP2 mature proteins, recruitment of SREBP proteins to lipogenic gene loci, lipid formation, cancer cell proliferation, and tumor growth in immunodeficient orthotopic xenografts and immunocompetent syngeneic TNBC mouse models. Interestingly, a 12-amino acid peptide derived from the DAXX C-terminal SIM spanning amino acid residues 729-740 (named SIM2) is cell-permeable and specifically suppresses DAXX interaction with precursor and mature SREBP proteins, but not with ATRX implicated in centromere histone H3.3 association, and also effectively inhibits cancer cell lipogenesis and tumor growth, highlighting a potential development of SIM2 as a therapeutic for cancer treatment via blocking DAXX-enhanced oncogenic lipogenesis.
- 5 November 2023
- Published by H1 Connect
Faculty Opinions recommendation of DAXX drives de novo lipogenesis and contributes to tumorigenesis.
This paper characterizes the oncogenic effects of death domain-associated protein 6 (DAXX) on intracellular lipogenesis primarily in MDA-MB-231 triple-negative breast cancer (TNBC) cells and identified that both N- and C-terminal SUMO-interacting motifs (SIMs) of DAXX are crucial for DAXX interaction with sterol regulatory element-binding protein 1 and 2 (SREBP1/2) precursors as well as cleaved SREBP1a, SREBP1c, and SREBP2 mature proteins, recruitment of SREBP proteins to lipogenic gene loci, lipid formation, cancer cell proliferation, and tumor growth in immunodeficient orthotopic xenografts and immunocompetent syngeneic TNBC mouse models. Interestingly, a 12-amino acid peptide derived from the DAXX C-terminal SIM spanning amino acid residues 729-740 (named SIM2) is cell-permeable and specifically suppresses DAXX interaction with precursor and mature SREBP proteins, but not with ATRX implicated in centromere histone H3.3 association, and also effectively inhibits cancer cell lipogenesis and tumor growth, highlighting a potential development of SIM2 as a therapeutic for cancer treatment via blocking DAXX-enhanced oncogenic lipogenesis.